Cosmo Bio Co

Cosmo Bio Co ROE

The Return on Equity (ROE) of Cosmo Bio Co (3386.T) as of Oct 26, 2026 is 3.58 %. In the previous year, Return on Equity (ROE) was 2.92 % — a change of 22.70% (higher).

ROE

3.58 %

YoY

22.70%

Last updated:

In 2025, Cosmo Bio Co's return on equity (ROE) was 3.58 %, a 22.70% increase from the 2.92 % ROE in the previous year.

The Cosmo Bio Co ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
3.95 JPY
Jan 1, 2019
3.46 JPY
Jan 1, 2020
9.16 JPY
Jan 1, 2021
9.46 JPY
Jan 1, 2022
6.42 JPY
Jan 1, 2023
5.23 JPY
Jan 1, 2024
2.92 JPY
Jan 1, 2025
3.58 JPY
The Cosmo Bio Co ROE history
YEARROEYoY
3.58 %+22.70%
2.92 %-44.18%
5.23 %-18.49%
6.42 %-32.16%
9.46 %+3.32%
9.16 %+164.48%
3.46 %-12.34%
3.95 %+6.37%
3.71 %-10.64%
4.16 %+7.54%
3.86 %+16.33%
3.32 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

ROE Details

Decoding Cosmo Bio Co's Return on Equity (ROE)

Cosmo Bio Co's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Cosmo Bio Co's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Cosmo Bio Co's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Cosmo Bio Co’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Cosmo Bio Co stock

Return on Equity (ROE) of Cosmo Bio Co is 3.58 % in 2025.

Return on Equity (ROE) of Cosmo Bio Co changed from 2.92 % to 3.58 %, representing a 22.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Cosmo Bio Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Cosmo Bio Co

All Key Metrics — Cosmo Bio Co